A detailed history of 683 Capital Management, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, 683 Capital Management, LLC holds 1,570,288 shares of ITOS stock, worth $12.2 Million. This represents 1.46% of its overall portfolio holdings.

Number of Shares
1,570,288
Previous 1,115,000 40.83%
Holding current value
$12.2 Million
Previous $16.5 Million 3.11%
% of portfolio
1.46%
Previous 1.51%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.09 - $17.97 $4.59 Million - $8.18 Million
455,288 Added 40.83%
1,570,288 $16 Million
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $4.13 Million - $7.24 Million
400,000 Added 55.94%
1,115,000 $16.5 Million
Q4 2023

Feb 14, 2024

SELL
$8.57 - $11.06 $814,150 - $1.05 Million
-95,000 Reduced 11.73%
715,000 $7.83 Million
Q3 2023

Nov 14, 2023

BUY
$10.95 - $14.6 $2.46 Million - $3.29 Million
225,000 Added 38.46%
810,000 $8.87 Million
Q2 2023

Aug 14, 2023

BUY
$12.93 - $18.05 $1.36 Million - $1.9 Million
105,000 Added 21.88%
585,000 $7.75 Million
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $4.3 Million - $7.46 Million
330,000 Added 220.0%
480,000 $6.53 Million
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $2.67 Million - $3.24 Million
150,000 New
150,000 $2.93 Million
Q4 2021

Feb 14, 2022

SELL
$26.23 - $47.86 $5.26 Million - $9.59 Million
-200,413 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$23.91 - $29.58 $4.79 Million - $5.93 Million
200,413 New
200,413 $5.41 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $276M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.